The VEGFR2-Akt-eNOS angiogenic cascade increases blood vessel formation by 129-152% in preclinical studies
TUE guidance documents including new regulations on glucocorticoids In order to assist physicians and athletes, in the last few weeks, WADA published the following guidance documents on managing TUEs to include the new regulations on glucocorticoids: General document on glucocorticoids and TUEs Checklists for athletes and treating physicians on a number of medical conditions for which glucocorticoids may be used TUE Physician Guidelines for TUE Committees on how to evaluate TUE requests for glucocorticoids for different medical conditions Educational resources In addition to the guidance documents listed above, WADA has provided a number of educational resources as part of its Code Implementation Support Program (CISP), which can be accessed on the Agencys Anti-Doping Education and Learning Platform (ADEL)
Side effects and safety BPC-157 has shown a favorable safety profile in animal studies, with low toxicity even at high doses
If you experience these or any other side effects after receiving an injection, contact your doctor as soon as possible
It does not invalidate the research, but it does mean human extrapolation should be conservative
The peptides used come from licensed 503A compounding pharmacies with FDA-mandated sterile manufacturing standards and third-party testing on each batch
